Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

Journal of Clinical Oncology

Volumn 13, Issue 1, 1995, Pages 180-190

  Gianni, Luca ^a   Kearns, Christine M ^b   Giani, Antonio ^b   Capri, Giuseppe ^b   Viganó, Lucia ^b   Locatelli, Alberta ^b   Bonadonna, Gianni ^b   Egorin, Merrill J ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6ALPHA HYDROXYTAXOL; CHLORPHENIRAMINE; CIMETIDINE; HYDROCORTISONE; PACLITAXEL; PACLITAXEL DERIVATIVE; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; OVARY CANCER; PREDICTION; PRIORITY JOURNAL;

EID: 0028894301     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1995.13.1.180     Document Type: Article

References (30)

1. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
2. Grem JL, Tutsch KD, Simon KJ, et al: Phase I study of Taxol administered as a short iv infusion daily for 5 days. Cancer Treat Rep 71:1179-1184, 1987
3. Wiernik PH, Schwartz EL, Einzig A, et al: Phase I trial of Taxol given as a 24-hour infusion every 21 days: Responses observed in metastatic melanoma. J Clin Oncol 5:1232-1239, 1987
4. Brown T, Havlin K, Weiss G, et al: A phase I trial of Taxol given by a 6-hour intravenous infusion. J Clin Oncol 9:1261-1267, 1991
5. Wiernik PH, Schwartz EL, Strauman JJ, et al: Phase I clinical and pharmacokinetic study of Taxol. Cancer Res 47:2486-2493, 1987
6. Longnecker SM, Donehower RC, Cates AE, et al: High-performance liquid chromatography assay for Taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53-59, 1987
7. Huizing MT, Keung AC, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
8. Gianni L, Capri G, Munzone E, et al: Paclitaxel efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 21:29-33, 1994 (suppl 8)
9. Harris JW, Katki A, Anderson LW, et al: Isolation, structural determination, and biological activity of 6α-hydroxytaxol, the principle human metabolite of Taxol. J Med Chem 37:706-709, 1994
10. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33:48-52, 1993
11. Rocci ML, Jusko WJ: LAGRAN program for area and moments in pharmacokinetic analysis. Comput Prog Biomed 16:293-216, 1983
12. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Prog Biomed 9:115-134, 1979
13. Steimer JL, Mallet A, Golmard JL, et al: Alternative approaches to estimation of population pharmacokinetic parameters: Comparison with the nonlinear mixed-effect model. Drug Metab Rev 15:265-292, 1984
14. Remington RD, Shork MA: Statistics with Applications to the Biological and Health Sciences. (ed 2). Englewood Cliffs, NJ, Prentice-Hall, 1985, p 145
15. Wagner JG: Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theoret Biol 20:173-201, 1968
16. DeLean A, Munson PJ: Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235:E97-E102. 1978
17. Kearns C, Gianni L, Giani A, et al: Non-linear pharmacokinetics of taxol in humans. Proc Am Soc Clin Oncol 12:135, 1993 (abstr)
18. Rowinsky EK, Donehower RC, Jones RJ, et al: Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48:4093-4100, 1988
19. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antineoplastic agent. J Natl Cancer Inst 82:1247-1259, 1990
20. Schiff PB, Fant J, Horowitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667, 1979
21. Wilson WH, Berg S, Kang YK, et al: Phase I/II study of taxol 96-hour infusion in refractory lymphoma and breast cancer: Pharmacodynamics and analysis of multi-drug resistance (mdr-1). Proc Am Soc Clin Oncol 12:134, 1993 (abstr 335)
22. Monsarrat B, Alvinerie P, Wright M, et al: Hepatic metabolism and biliary clearance of Taxol in rats and human. J Natl Cancer Inst Monogr 15:39-46, 1993
23. Kumar GN, Walle UK, Walle T: Cytochrome P450 3A-mediated human liver microsomal Taxol 6a-hydroxylation. J Pharmacol Exp Ther 268:1160-1164, 1994
24. Walle T: 6α-hydroxytaxol: Isolation and identification of the major metabolite of Taxol in human liver microsomes. Drug Metab Disp 22:177-179, 1994
25. Cresteil T, Monsarrat B, Alvinerie P, et al: Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386-392, 1994
26. Sonnichsen D, Hurwitz CA, Pratt CB, et al: Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12:532-538, 1994
27. Rowinsky EK, Burke PJ, Karp JE, et al: Phase I and pharmacodynamic study of Taxol in refractory acute leukemias. Cancer Res 49:4640-4647, 1989
28. Sarosy G, Kohn E, Stone DA, et al: Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165-1170, 1992
29. Kohn EC, Sarosy G, Bicher A, et al: Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:18-24, 1994
30. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991